Thursday, October 15, 2026

China Petroleum & Chemical Corporation And 3 Other Stocks Have Very High Payout Ratio

ViaNews Editorial Team

January 5, 2021

China Petroleum & Chemical Corporation And 3 Other Stocks Have Very High Payout Ratio

We have congregated information concerning stocks with the highest payout ratio so far. The payout ratio in itself isn't a assurance of good investment but it's an indicator of whether dividends are being paid and how the company chooses to distribute them.

When researching a potential investment, the dividend payout ratio is a good statistic to know and anything around 60 percent is considered high.

1. RE/MAX Holdings, Inc.

126.09% Payout Ratio

RE/MAX Holdings, Inc. operates as a franchisor of real estate and mortgage brokerage services in the United States, Canada, and internationally.

According to Morningstar, Inc., the next dividend payment is on Nov 16, 2020, the estimated forward annual dividend rate is 0.88 and the estimated forward annual dividend yield is 2.4%.

RE/MAX Holdings, Inc.'s sales growth this year is expected to be negative 6.3% and 10.5% for next year.

Year-on-year quarterly revenue growth declined by 0.7%, now sitting on 261.74M for the twelve trailing months.

RE/MAX Holdings, Inc.'s sales growth is 3.2% for the ongoing ongoing quarter and 5% for the next. The company's growth estimates for the present quarter and the next is negative 4.3% and 7.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.77%.

Volatility

RE/MAX Holdings, Inc.'s last day, last week, and last month's average volatility was a negative 1.75%, a negative 1.13%, and a positive 0.69%, respectively.

RE/MAX Holdings, Inc.'s last day, last week, and last month's high and low average amplitude percentage was 2.94%, 3.49%, and 3.29%, respectively.

RE/MAX Holdings, Inc.'s Stock Yearly Top and Bottom Value

RE/MAX Holdings, Inc.'s stock is valued at $36.10 at 16:23 EST, way below its 52-week high of $40.78 and way above its 52-week low of $14.40.

RE/MAX Holdings, Inc.'s Moving Average

RE/MAX Holdings, Inc.'s value is higher than its 50-day moving average of $33.58 and above its 200-day moving average of $33.62.

2. Nuveen Massachusetts Premium Income Municipal Fund

118.81% Payout Ratio

Nuveen Massachusetts Quality Municipal Income Fund is a closed ended fixed income mutual fund launched by Nuveen Investments, Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC.

According to Morningstar, Inc., the next dividend payment is on Dec 13, 2020, the estimated forward annual dividend rate is 0.55 and the estimated forward annual dividend yield is 3.82%.

Nuveen Massachusetts Premium Income Municipal Fund's sales growth this year is expected to be negative 0% and a negative 0% for next year.

Year-on-year quarterly revenue growth declined by 4.6%, now sitting on 7.85M for the twelve trailing months.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.86%.

Volatility

Nuveen Massachusetts Premium Income Municipal Fund's last day, last week, and last month's average volatility was a positive 0.76%, a positive 0.19%, and a negative 0.10%, respectively.

Nuveen Massachusetts Premium Income Municipal Fund's last day, last week, and last month's high and low average amplitude percentage was 2.79%, 1.09%, and 0.81%, respectively.

Nuveen Massachusetts Premium Income Municipal Fund's Stock Yearly Top and Bottom Value

Nuveen Massachusetts Premium Income Municipal Fund's stock is valued at $14.60 at 16:23 EST, under its 52-week high of $14.98 and way higher than its 52-week low of $11.25.

Nuveen Massachusetts Premium Income Municipal Fund's Moving Average

Nuveen Massachusetts Premium Income Municipal Fund's value is higher than its 50-day moving average of $14.53 and higher than its 200-day moving average of $14.23.

3. China Petroleum & Chemical Corporation

60.65% Payout Ratio

China Petroleum & Chemical Corporation, an energy and chemical company, engages in oil and gas, and chemical operations in the People's Republic of China.

According to Morningstar, Inc., the next dividend payment is on Oct 13, 2020, the estimated forward annual dividend rate is 4.37 and the estimated forward annual dividend yield is 9.7%.

China Petroleum & Chemical Corporation's sales growth this year is anticipated to be negative 1.5% and a negative 25.1% for next year.

Year-on-year quarterly revenue growth declined by 29.1%, now sitting on N/A for the twelve trailing months.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.6%.

Volatility

China Petroleum & Chemical Corporation's last day, last week, and last month's average volatility was 0.38%, 0.87%, and 0.01%, respectively.

China Petroleum & Chemical Corporation's last day, last week, and last month's high and low average amplitude percentage was 0.82%, 1.18%, and 1.33%, respectively.

China Petroleum & Chemical Corporation's Stock Yearly Top and Bottom Value

China Petroleum & Chemical Corporation's stock is valued at $45.22 at 16:23 EST, way under its 52-week high of $62.22 and way higher than its 52-week low of $38.18.

China Petroleum & Chemical Corporation's Moving Average

China Petroleum & Chemical Corporation's worth is under its 50-day moving average of $45.37 and above its 200-day moving average of $43.51.

4. Standard Register Company

172.92% Payout Ratio

Spire Inc., through its subsidiaries, engages in the purchase, retail distribution, and sale of natural gas to residential, commercial, industrial, and other end-users of natural gas in the United States.

According to Morningstar, Inc., the next dividend payment is on Dec 9, 2020, the estimated forward annual dividend rate is 2.6 and the estimated forward annual dividend yield is 4.13%.

Standard Register Company's sales growth this year is anticipated to be 1.9% and 5% for next year.

Year-on-year quarterly revenue growth grew by 11.7%, now sitting on 1.86B for the twelve trailing months.

Standard Register Company's sales growth for the next quarter is 8.3%. The company's growth estimates for the ongoing quarter and the next is negative 3% and 10.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.5%.

Volatility

Standard Register Company's last day, last week, and last month's average volatility was a positive 0.60%, a positive 0.08%, and a negative 0.05%, respectively.

Standard Register Company's last day, last week, and last month's high and low average amplitude percentage was 1.83%, 1.91%, and 2.41%, respectively.

Standard Register Company's Stock Yearly Top and Bottom Value

Standard Register Company's stock is valued at $63.37 at 16:23 EST, way below its 52-week high of $87.96 and way above its 52-week low of $50.58.

Standard Register Company's Moving Average

Standard Register Company's worth is under its 50-day moving average of $64.29 and higher than its 200-day moving average of $60.75.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com